CAH · Cardinal Health Inc
Price
Snapshot
50 fields · last close| Market Cap | $58.83B |
| P/E | 34.32 |
| Float | 233.6M |
| Beta | 0.54 |
| Volatility | 13.4% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 83.3 |
| Price | 250.45 |
| Change | −1.42% |
| Prev Close | 254.06 |
| Open | 254.81 |
| Day Low | 251.95 |
| Day High | 255.56 |
| Avg Vol | 1 |
| Avg $ Vol | $368.0M |
| 52W High | 258.30 |
| 52W Low | 152.46 |
| 52W Pos | 92.6% |
| From High | −3.04% |
| From Low | +64.27% |
| Max DD 1Y | −20.61% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +7.82% |
| SMA 50 | +6.85% |
| SMA 200 | +13.92% |
| RSI (14) | 74.1 |
| Vol 30D | 24.5% |
| Vol 90D | 23.2% |
| 1Y Range | 152–258 |
| Daily bars | 537 |
| Perf Week | +6.94% |
| Perf Month | +12.25% |
| Perf Quarter | +12.54% |
| Perf Half Y | +20.30% |
| Perf Year | +65.76% |
| Perf YTD | +21.74% |
| Prev Day | −1.42% |
| Clavix | A- |
| Debt / Eq | 3.48 |
| Curr Ratio | 0.88 |
| Int Cover | 7.2× |
| FCF Margin | 1.8% |
| Rev Growth | +14.2% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 4 / 49 |
What CAH does
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally.
It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.
The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products.
The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products.
In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines.
Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits.
Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions.
The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Clavix risk grade
regraded every trading dayCAH grades A-, 83.3 of 100. Steadiest on Sector Resilience (69), most exposed on News Sentiment (65, steady). 4 of the 4 weighted dimensions sit above the Health Care median. Ranks 4 of 49 in Health Care by Clavix score.
How rough the ride is
| CAH | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.54 | 0.84 |
| Volatilityannualized | 13.4% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −20.6% | — |
| Typical daily movemedian absolute daily change | 0.83% | — |
| Days beyond ±3%of the last 252 sessions | 12 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CAH | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.54 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CAH | |
|---|---|
| 1 week | +6.9% |
| 1 month | +12.2% |
| Year to date | +21.7% |
| 1 year | +65.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CAH | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 8 Sep |
| Average score0 most bearish, 100 most bullish | 64 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 2 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| CAH | |
|---|---|
| Revenue growthyear over year | +14.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openWall Street Zen lowered its rating on Cardinal Health (CAH) from 'strong-buy' to 'buy.' The article reports only the rating change and no company-specific business development.
The article makes a case for holding onto Cardinal Health (CAH) stock, arguing that as the company enters fiscal 2027, growth in Pharmaceutical segment profits, new emerging business areas, and cost-saving improvements are expected to outweigh ongoing revenue pressures.
An article lays out reasons to hold Cardinal Health stock, noting the company is entering fiscal 2027 with profit growth in its Pharma business, new growth areas, and cost efficiencies, though these are working against a decline in overall revenue.
Cardinal Health announced in October 2026 that it signed a binding Letter of Intent to extend its existing drug distribution agreement with CVS Health through June 30, 2032, keeping the current scope of services in place.
Cardinal Health issued its fiscal 2027 earnings outlook, guiding to profit of $12.40-$12.60 per share, which brackets the $12.56 per share analysts had been expecting. The company did not provide a revenue figure, and several analysts issued new price targets for the stock.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corp | B | $64.33B | 17.51 | 0.59 | Compare |
| COR | Cencora Inc | B+ | $65.06B | 24.79 | 0.58 | Compare |
| BDX | Becton Dickinson and Co | A- | $52.23B | 55.45 | 0.24 | Compare |
| VEEV | Veeva Systems Inc | B- | $50.25B | 49.52 | 0.88 | Compare |
| EW | Edwards Lifesciences Corp | A- | $49.92B | 49.67 | 0.84 | Compare |
| HUM | Humana Inc | B | $49.61B | 38.79 | 0.67 | Compare |
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
| IDXX | IDEXX Laboratories Inc | B+ | $44.15B | 38.74 | 1.55 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.